Refrences.
- Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M,
Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory:
Cancer Today. Lyon, France: International Agency for Research on
Cancer. Available from: https://gco.iarc.who.int/today, accessed
[27/Feburary/ 2025].
- Campbell SC, Lane BR. Malignant renal tumors. Campbell-Walsh Urology.
2012:1413-74.
- Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic
malignancy: the many faces of renal cell carcinoma. Reviews in
urology. 2002;4(4):163.
[4] Edge SB, American Joint Committee on Cancer AC. AJCC cancer
staging handbook: from the AJCC cancer staging manual. New York:
Springer; 2010.
[5]
”Kidney
Cancer”. National Cancer Institute.
2019. Archived from
the original on 15 August 2020. Retrieved 8 June 2019.
[6] Cairns P. Renal cell carcinoma. Cancer biomarkers. 2011 Jan
1;9(1-6):461-73.
[7] Lee J, Chae HK, Lee W, Nam W, Lim B, Choi SY, Kyung YS, You D,
Jeong IG, Song C, Hong B. Comparison of prognosis in types 1 and 2
papillary renal cell carcinoma and clear cell renal cell carcinoma in T1
stage. The Korean Journal of Urological Oncology. 2018 Dec
28;16(3):119-25.
[8]
”Kidney
Cancer - Risk Factors and Prevention”. Cancer.Net.
2012-06-25. Archived from
the original on 2019-12-02. Retrieved 2019-12-02.
[9]
”Hereditary
Papillary Renal Carcinoma”. Cancer.Net. 2012-06-25.
Retrieved 2020-04-08.
- Mancilla‐Jimenez R, Stanley RJ, Blath RA. Papillary renal cell
carcinoma. A clinical, radiologic, and pathologic study of 34 cases.
Cancer. 1976 Dec;38(6):2469-80.
- Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ.
Prognostic utility of the recently recommended histologic
classification and revised TNM staging system of renal cell carcinoma:
a Swiss experience with 588 tumors. Cancer. 2000 Aug 1;89(3):604-14.
- Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles
RH, Moch H. Chromophobe renal cell carcinoma: histomorphologic
characteristics and evaluation of conventional pathologic prognostic
parameters in 145 cases. The American journal of surgical pathology.
2008 Dec 1;32(12):1822-34.
- Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of
outcome and prognostic features among histologic subtypes of renal
cell carcinoma. The American journal of surgical pathology. 2003 May
1;27(5):612-24.
- Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, Venturina MD,
Deshpande A, Menon M. Prognostic impact of histologic subtyping of
adult renal epithelial neoplasms: an experience of 405 cases. The
American journal of surgical pathology. 2002 Mar 1;26(3):281-91.
- Beck SD, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, Russo
P. Effect of papillary and chromophobe cell type on disease-free
survival after nephrectomy for renal cell carcinoma. Annals of
surgical oncology. 2004 Jan;11:71-7.
- Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute
ML, Cheville JC. Histological subtype is an independent predictor of
outcome for patients with renal cell carcinoma. The Journal of
urology. 2010 Apr;183(4):1309-16.
- Gontero P, Ceratti G, Guglielmetti S, Andorno A, Terrone C, Bonvini D,
Faggiano F, Tizzani A, Frea B, Valente G. Prognostic factors in a
prospective series of papillary renal cell carcinoma. BJU
international. 2008 Sep;102(6):697-702.
- Ljungberg B, Alamdari FI, Stenling R, Roos G. Prognostic significance
of the Heidelberg classification of renal cell carcinoma. European
urology. 1999 Dec 1;36(6):565-9.
- Delahunt B, Eble JN. Papillary renal cell carcinoma: a
clinicopathologic and immunohistochemical study of 105 tumors. Modern
pathology: an official journal of the United States and Canadian
Academy of Pathology, Inc. 1997 Jun 1;10(6):537-44.
- Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM.
Morphologic typing of papillary renal cell carcinoma: comparison of
growth kinetics and patient survival in 66 cases. Human pathology.
2001 Jun 1;32(6):590-5.
- Zeng Q, Luo S, Chen L, Chen L, Chen J. Bladder metastasis from type 2
papillary renal cell carcinoma: A case report. Oncology Letters. 2023
May 5;25(6):270.
- Kosaka T, Mikami S, Miyajima A, Oya M. Metastatic type-2 papillary
renal cell carcinoma responded to interleukin-2 therapy: case report.
Clinical and experimental nephrology. 2008 Apr;12:155-8.
- Tomlinson, IP, Alam, NA, Rowan, AJ, et al. Germline mutations in FH
predispose to dominantly inherited uterine fibroids, skin leiomyomata
and papillary renal cell cancer. Nat Genet 2002;30:406-410
- Schmidt, LS, Junker, K, Nakaigawa, N, et al. Novel mutations of the
MET proto-oncogene in papillary renal
carcinomas. Oncogene 1999;18:2343-2350
- Durinck, S, Stawiski, EW, Pavía-Jiménez, A, et al. Spectrum of diverse
genomic alterations define non-clear cell renal carcinoma
subtypes. Nat Genet 2015;47:13-21
- Harrison WJ, Andrici J, Maclean F, Madadi-Ghahan R, Farzin M, Sioson L
et al. Fumarate hydratase-deficient uterine leiomyomas occur in both
the syndromic and sporadic settings. American Journal of Surgical
Pathology. 2016 May;40(5):599-607. doi: 10.1097/PAS.0000000000000573
- Kapila V, Kalra AG, Stockman DL, Kapila-Kalra V. A non-hereditary case
of hereditary leiomyomatosis and renal cell carcinoma syndrome.
Cureus. 2021 Feb 15;13(2).
- Xia S, Lin Y, Lin J, Li X, Tan X, Huang Z. Increased expression of
TICRR predicts poor clinical outcomes: a potential therapeutic target
for papillary renal cell carcinoma. Frontiers in Genetics. 2021 Jan
11;11:605378.
- Cancer Genome Atlas Research Network. Comprehensive molecular
characterization of papillary renal-cell carcinoma. New England
Journal of Medicine. 2016 Jan 14;374(2):135-45.
- Pal SK, Ali SM, Yakirevich E, et al. Characterization of clinical
cases of advanced papillary renal cell carcinoma via comprehensive
genomic profiling. Eur Urol 2018
[31]
[32] Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal
cell carcinoma [Figure presented]. Eur Urol 2019.
[33] Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of
renal cell carcinoma. Eur Urol 2011.
[34] Woldu SL, Weinberg AC, RoyChoudhury A, et al. Renal
insufficiency is associated with an increased risk of papillary renal
cell carcinoma histology. Int Urol Nephrol 2014.
[35] Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney
and urinary tract in patients on dialysis for end-stage renal disease:
Analysis of data from the United States, Europe, and Australia and New
Zealand. J Am Soc Nephrol 2003.
Park JH, Kim YO, Park JH, et al. Comparison of acquired cystic kidney
disease between hemodialysis and continuous ambulatory peritoneal
dialysis. Korean J Intern Med 2000.
Shuch B, Hahn AW, Agarwal N. Current treatment landscape of advanced
papillary renal cancer. J Clin. Oncol. 2017; 35 (26):
https://ascopubs.org/doi/10.1200/JCO.2017.74.3328
[38] Sung H, Jiang C, Bandi P, Minihan A, Fidler-Benaoudia M, Islami
F, Siegel RL, Jemal A. Differences in cancer rates among adults born
between 1920 and 1990 in the USA: an analysis of population-based cancer
registry data. The Lancet Public Health. 2024 Aug 1;9(8):e583-93.